AirJoule Technologies Corp. reported a significant net loss of $78.2 million for the nine months ended September 30, 2026, primarily driven by a $91.5 million equity loss from its investment in AirJoule, LLC. This compares to a net income of $13.4 million in the prior year period, which had been bolstered by favorable changes in the fair value of derivative liabilities.
Jaguar Health reported its third quarter 2026 financial results, highlighting a significant $10.1 million reduction in outstanding debt. The company is transitioning to a distribution and R&D model following its U.S. commercial licensing agreement with Woodward Specialty, focusing on its rare disease intestinal failure program for crofelemer.
Stewards, Inc. reported Q3 2026 financial results, highlighting a 49% increase in total assets to $265.3 million following the acquisition of Envy Pompano Beach and the refinancing of 1818 Park. The company reported a net loss of $19.4 million on revenue of $3.4 million, impacted by non-cash warrant liability changes and lower private credit deployment.
Term
Q3 2026
“The third quarter marked a major step forward for Stewards. We began trading on Nasdaq, completed the $79 million refinancing of 1818 Park, acquired Envy and grew total assets to $265.3 million. We also launched our digital customer portal, put the Plaid integration into operation and advanced the Stewards Business Card with Rain. We have moved quickly to expand the platform across real assets, private credit and technology. Our focus now is turning that expansion into results by improving property performance, increasing private credit deployment as funding capacity expands and moving the Business Card toward initial availability for qualified customers.”
INVO Fertility, Inc. reported total revenue of $6.41 million for the nine months ended September 30, 2026, a 22% increase over the prior year, primarily driven by clinic revenue growth. Despite the revenue increase, the company realized a net loss from continuing operations of $6.71 million, impacted by significant non-cash items including a $4.35 million loss on the change in fair value of derivatives.
New Fortress Energy reported a significant financial turnaround in Q3 2026, recording net income of $863.4 million compared to a net loss of $263.0 million in the prior year, largely driven by a $1.18 billion gain on debt restructuring. The company also executed a 1-for-50 reverse stock split in September 2026 and issued $2.46 billion in Series A Mandatorily Convertible Preferred Stock.
New Fortress Energy reported Q3 2026 financial results, highlighting the completion of its restructuring and recapitalization which reduced debt principal from $5.7 billion to $0.7 billion. The company reported net income of $863.4 million, primarily driven by a $1.6 billion non-cash gain on debt extinguishment, though it issued a going-concern warning due to the temporary outage of its FLNG 1 facility.
“With our restructuring complete, we are now a transformed company with significantly reduced debt and a simplified, capital-light business plan. Our power assets are in great demand and the worldwide need for LNG continues to be robust. As we execute on our business plan, we are focused on leveraging our assets to generate strong returns and positive cash flow from operations.”
Eloxx Pharmaceuticals reported Q3 2026 financial results and provided a business update on its rare kidney disease pipeline, including the dosing of the first two patients in the Phase 2b EXACT study for Alport syndrome. The company also received FDA IND clearance for its Phase 2 EXPRESS study in ADPKD and ended the quarter with $56.3 million in cash.
Term
Q3 2026
“The third quarter marked important progress for Eloxx, as we dosed the first two patients in our Phase 2b EXACT study in nonsense mutation Alport syndrome. With the EXPRESS protocol finalized and IND clearance in hand, we now have two programs in rare kidney disease.”
Sumit Aggarwal, President and Chief Executive Officer
BioAtla, Inc. reported a significant reduction in net loss to $13.8 million for the first nine months of 2026, compared to $49.8 million in the prior year, primarily driven by $6.8 million in collaboration revenue and a sharp decrease in R&D spending. However, the company's liquidity position is critical, with cash and cash equivalents dropping to $0.6 million as of September 30, 2026, and a total stockholders' deficit of $43.6 million.
Radnostix Inc. reported a significant increase in net loss to $3.07 million for the nine months ended September 30, 2026, compared to $0.48 million in the prior year, driven by a 25% decline in product sales. The company's total equity decreased from $3.69 million to $1.93 million during the period as operating expenses rose despite the revenue contraction.
For the nine months ended September 30, 2026, Kartoon Studios reported a net income of $14.8 million, a significant turnaround from a $19.4 million loss in the prior year, primarily driven by $26.6 million in other income. However, total revenues declined to $18.4 million from $29.7 million year-over-year, largely due to a decrease in production services revenue.
Q/C Technologies reported a net loss of $11.3 million for the nine months ended September 30, 2026, driven by significant stock-based compensation and a $3.2 million impairment of a technology license. The company remains pre-revenue, with its accumulated deficit increasing to $155.9 million and total stockholders' equity declining to $16.1 million.
Nexentis Technologies Inc. reported a net loss of $12.7 million for the nine months ended September 30, 2026, significantly impacted by a $6.3 million goodwill impairment. Despite the year-to-date loss, the company achieved a net gain of $5.0 million in the third quarter of 2026, primarily driven by $7.1 million in financing income.
Canton Strategic Holdings, Inc. reported a significant net loss of $101.7 million for the nine months ended September 30, 2026, primarily driven by a $93.4 million unrealized loss on digital asset holdings. The company has transitioned its strategy toward a digital asset treasury and network validation, reporting its first $4.5 million in revenue from these operations during the period.
Range Impact, Inc. reported a net loss of $7.67 million for the nine months ended September 30, 2026, compared to a net income of $3.26 million in the prior year period. The shift was primarily driven by a $5.6 million gain on bargain purchase in 2025 that did not recur, alongside significant increases in accretion of asset retirement obligations and amortization of intangible assets.
Kartoon Studios reported its Q3 2026 financial results, highlighting a cash and marketable securities position of $33.0 million. The company is shifting its strategy toward owning and commercializing high-value IP, including the upcoming launch of 'Hundred Acre Wood' on Amazon Prime and Walmart Marketplace in early 2027.
Term
Q3 2026
“We are building a fundamentally different Kartoon Studios, with ownership of great intellectual property at the center of our business and multiple ways to turn that creativity into lasting shareholder value. Our agreements with Amazon Prime and Walmart Marketplace bring that strategy to life, connecting entertainment with opportunities for families to discover and purchase products featuring our characters.”
Andy Heyward, Chairman and Chief Executive Officer
Yan Chuang Group Inc. is a startup fintech company that has not yet generated revenue and reported a net loss of $26,715 for the quarter ended September 30, 2026. The company significantly increased its cash position to $626,089 through the issuance of common stock, though management expressed concerns regarding its ability to continue as a going concern without further capital.
Ainos reported Q3 2026 financial results with revenue increasing significantly to $642,889, driven by VELDONA licensing and AI Nose semiconductor programs. The company narrowed its GAAP net loss by 36% year-over-year and highlighted a subsequent $9 million follow-on order for its AI Nose systems.
“Our third-quarter results show progress in translating commercial agreements into revenue. Revenue reached $642,889, up 29,567% year over year, driven by VELDONA licensing and our AI Nose semiconductor program. We delivered 1,400 AI Nose systems under our initial $2.1 million agreement and received initial orders from another semiconductor customer.”
Eddy Tsai, Chairman, President and Chief Executive Officer
“Our Q3 2026 results demonstrate progress in both revenue generation and operating discipline. GAAP net loss improved 36% year over year while non-GAAP adjusted net loss improved 51%. GAAP gross margin increased to 83.4% from 78.0% in the third quarter of 2025, while non-GAAP gross margin increased to 83.6% from 78.0%, excluding share-based compensation and depreciation and amortization allocated to cost of revenue.”
Aptevo Therapeutics reported a net loss of $6.5 million for the quarter ended September 30, 2026, and a net loss attributable to common stockholders of $9.3 million after accounting for a $2.8 million deemed dividend. The company's cash position decreased significantly from $21.6 million at the end of 2025 to $8.3 million as of September 30, 2026, primarily due to $19.1 million used in operating activities.
Canton Strategic Holdings reported its third quarter 2026 financial results, achieving its first positive Adjusted EBITDA of $0.6 million. Total revenue grew 104% sequentially to $3 million, driven by the first full quarter of Super Validator and locking-as-a-service operations. The company reported a net loss of $35.1 million, primarily reflecting non-cash items as it continues to scale its Canton Network strategy.
“We are proud to have achieved our first positive Adjusted EBITDA this quarter, a notable milestone as we mark the first year of operations since our launch in November 2025. With a full year under our belt as a publicly traded company operating our CC strategy, we remain focused on growth. Our Super Validator operations and locking-as-a-service offering allow us to support the Canton Network and its participants while also earning revenue that we can deploy for continued investment in the ecosystem and enhanced value for shareholders. With our operating cost base largely fixed and clear visibility to additional approved Super Validator weight, we believe the business is positioned for significant operating leverage and margin expansion.”
Mark Wendland, Chairman and Chief Executive Officer
Cycurion reported record quarterly revenue of $5.4 million for Q3 2026, a 40% increase year-over-year, driven by recent acquisitions and a return to growth in existing operations. Gross profit increased more than sevenfold to $1.9 million, while the company's operating loss narrowed by 35% to $3.0 million.
Term
Q3 2026
“Our third-quarter results demonstrate the momentum we are building at Cycurion. Higher-margin revenue translated into substantially more gross profit, and we narrowed our operating and adjusted EBITDA losses. We also returned to revenue growth in our existing operations while adding contributions from our acquisitions. We are encouraged by this progress and focused on carrying it forward.”
L. Kevin Kelly, Chairman and Chief Executive Officer
“We see a significant opportunity ahead. Our acquisitions have expanded our capabilities and customer reach, and our predictive intelligence strategy gives us more ways to help customers identify and address their most consequential threats. Our team, which includes veterans of the U.S. Intelligence Community and the private-sector cybersecurity industry, is focused on converting those opportunities into recurring revenue, stronger gross profit and continued progress toward profitability. We are building on a stronger operating foundation while maintaining expense discipline and working to improve operating cash flow.”
L. Kevin Kelly, Chairman and Chief Executive Officer
StablecoinX reported its third quarter 2026 financial results, highlighting a 666% sequential revenue increase to $0.48 million driven by its Decentralized Verifier Node (DVN) infrastructure. The company reported a GAAP net loss of $100.2 million, primarily due to non-cash warrant liability adjustments, while its ENA token treasury was valued at approximately $802 million at quarter-end.
Term
Q3 2026
“Our third quarter performance provided an initial indication of the value StablecoinX was built to deliver. Our verifier infrastructure doubled its cumulative verified volume to more than $6 billion in less than two months, which increased revenue nearly eightfold sequentially.”
Aptevo Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a business update on its clinical pipeline. The company highlighted a 79% remission rate for its lead candidate mipletamig in high-risk TP53-mutated AML patients, which is nearly double the historical benchmark for standard-of-care treatments.
“We are entering an exciting period for Aptevo, with growing clinical evidence that reinforces our confidence in mipletamig and meaningful progress across our broader pipeline. We are seeing strong clinical activity in patients with some of the most difficult-to-treat forms of AML, patients advancing to potentially curative stem cell transplantation, and important improvements in tolerability.”
Jeff Lamothe, President and Chief Executive Officer of Aptevo
“As we approach important clinical and development milestones, we believe Aptevo is increasingly well positioned to translate the strength of our science into meaningful opportunities for patients and long-term value for shareholders.”
Jeff Lamothe, President and Chief Executive Officer of Aptevo
Professional Diversity Network reported a total revenue of $3.44 million for the nine months ended September 30, 2026, a decrease from $4.61 million in the prior year. The company experienced a net loss of $5.98 million during this period, driven by significantly higher depreciation and amortization expenses and a decline in recruitment services revenue.
Larimar Therapeutics reported a net loss of $31.1 million for the third quarter of 2026, an improvement from the $47.7 million loss in the prior year period, primarily driven by a significant decrease in research and development expenses. The company strengthened its balance sheet through equity issuances, ending September 30, 2026, with $128.7 million in cash, cash equivalents, and marketable securities.
Professional Diversity Network reported Q3 2026 financial results, showing a 48.2% revenue decline to $0.86 million, primarily due to reduced demand in its TalentAlly and RemoteMore segments. Despite the revenue drop, the company improved its working capital to $0.2 million and launched a new GPU computing initiative through PDN Intelligence, Inc. to enter the AI infrastructure market.
Term
Q3 2026
“Our third quarter results reflect our continued focus on financial discipline, operational efficiency, and strategic business development. We have made meaningful progress in strengthening our working capital position and managing operating expenses while continuing to explore new growth opportunities.”
Bella Gu, Chief Executive Officer and Chief Financial Officer
“The launch of our graphics processing unit (“GPU”) computing initiative through PDN Intelligence, Inc. represents an important step in our strategy to expand into artificial intelligence (“AI”) infrastructure and computing services.”
Bella Gu, Chief Executive Officer and Chief Financial Officer
HeartCore Enterprises reported a significant decline in revenue to $269,852 for the nine months ended September 30, 2026, compared to $1,666,519 in the prior year, resulting in a net loss of $3,792,658. The company underwent a 1-for-20 reverse stock split on April 2, 2026, and is currently managing the disposal of discontinued operations.
HCW Biologics reported financial results for the third quarter of 2026, highlighting progress in its HCW9302 Phase 1 clinical study for alopecia areata and the presentation of its TRBC platform molecules at SITC2026. The company recently secured up to $10.0 million in debt financing to support its clinical and preclinical programs through the Phase 1 readout expected in Q1 2027.
Term
Q3 2026
“Progress continues steadily for our clinical study evaluating HCW9302 in alopecia areata, and we are encouraged by results in humans that are consistent with our preclinical studies. We have the support of strong clinical sites who share our passion for developing breakthrough immunotherapeutics. With the addition of a third clinical site, we are hopeful that patient enrollment will maintain a good momentum as we come to the end of the Phase 1 clinical study. We are also excited about the great progress we have made with the molecules we have constructed using our TRBC platform, especially our lead T-cell engager, HCW11-018b, and our lead second-generation immune-checkpoint inhibitor, HCW11-040, which have the potential of revolutionizing treatment for solid tumors and senescence-associated diseases.”
Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer
Virginia National Bankshares Corp reported net income of $6.6 million for the third quarter of 2026, a significant increase from $4.6 million in the same period of 2025. This growth was driven by higher net interest income and a $4.7 million gain on the sale of a limited partnership investment during the nine-month period.
HCW Biologics Inc. reported a significant revenue increase to $6.7 million for the nine months ended September 30, 2026, primarily driven by a $3.5 million noncash licensing agreement. Despite this, the company recorded a net loss of $5.0 million for the period and an accumulated deficit of $113.5 million, reflecting ongoing research and development costs and substantial equity dividends to investors.
RenX Enterprises reported record Q3 2026 revenue of $4.48 million, representing 27.5% year-over-year growth and its third consecutive quarter of sequential growth. The company achieved a record gross margin of 34.3% and completed construction of its Microtec mill, with production expected to begin in January 2027.
Term
Q3 2026
“RenX grew revenue every quarter of 2026, expanded gross margin to its best level of the year, and delivered a third straight profitable quarter in Logistics. That is fundamental growth, quarter after quarter, generated by operations.”
David Villarreal, Chief Executive Officer of RenX Enterprises Corp.